本帖最后由 老马 于 2012-1-13 21:20 编辑
& q) W- G: _/ f0 v( o8 J" _; E* P: Q5 z3 C) k/ {. s
爱必妥和阿瓦斯丁的比较
5 [. U R7 Y2 z( D* z# y5 y0 c
+ e! o0 Q# @) W6 Bhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
. y4 F0 O. u8 q/ h) }) N1 {' e( ]
, x6 l, k% f" b* p/ }! D
- A( K+ K Z/ Q4 g( D$ _http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/0 t$ H9 H2 x" R0 F7 l, {! B
==================================================
- |7 K) i* y" h6 m5 e, DOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
9 C) ~2 |& D* [# H: }Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.# X& s& Y& E2 {, [
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.# i$ F% V3 O" ? a
|
显身卡
